Results 81 to 90 of about 379,801 (144)

Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV. [PDF]

open access: yesSci Rep, 2023
Kim JY   +30 more
europepmc   +1 more source

Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly. [PDF]

open access: yesCell Rep, 2023
Ferreira IATM   +32 more
europepmc   +1 more source

No changes in hemostasis after COVID-19-heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study. [PDF]

open access: yesRes Pract Thromb Haemost, 2023
Butta NV   +17 more
europepmc   +1 more source

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile. [PDF]

open access: yesFront Public Health, 2023
Díaz-Dinamarca DA   +25 more
europepmc   +1 more source

Vaccination status of COVID-19 patients followed up in the ICU in a country with heterologous vaccination policy: A multicenter national study in Turkey. [PDF]

open access: yesJ Infect Chemother, 2023
Yıldırım S   +35 more
europepmc   +1 more source

Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination. [PDF]

open access: yesFront Immunol, 2023
Lo Tartaro D   +19 more
europepmc   +1 more source

Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273. [PDF]

open access: yesSignal Transduct Target Ther, 2023
Hernández J   +8 more
europepmc   +1 more source

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac Plus BNT162b2: A Prospective Cohort Study [PDF]

open access: yesVaccines (Basel), 2022
Demirhindi H   +7 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy